Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for ...

It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

The top U.S. Food and Drug Administration official on Tuesday confirmed AstraZeneca Plc's U.S. COVID-19 vaccine trial is on ...

About 1 in 4 American adults got a covid vaccine shot during the 2024-25 virus season, a fraction health care experts warn could be smaller this year as millions wrestle with conflicting advice from ...

The inequitable distribution of vaccines during the COVID-19 pandemic was the final proof of the need for more home-grown ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...